TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06660303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Preoperative Education for Enhanced Recovery in Colorectal Surgery
Description: The intervention in this study involves preoperative patient education aimed at improving outcomes for individuals undergoing colorectal surgery. Patients in the study group will receive targeted educational sessions that focus on setting expectations, managing anxiety, understanding pain control, and preparing for the surgical process as part of the Enhanced Recovery After Surgery (ERAS) protocol. This educational approach is designed to empower patients, reduce anxiety, enhance satisfaction, and potentially improve post-surgical recovery compared to those receiving routine hospital care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine hospital care
Description: The control group, designated as Group II, will receive standard hospital care, encompassing the usual preoperative and postoperative procedures provided by the hospital. This includes typical preparation and recovery guidelines without any added specialized preoperative education or targeted nursing instructions. This routine hospital care serves as a baseline, allowing for a direct comparison of outcomes against the intervention group, which will receive comprehensive preoperative education aimed at enhancing recovery and improving surgical outcomes.
Study: NCT06658743

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared Medical Appointments
Description: Participants will attend 4 quarterly appointments. In addition to time with their clinician, they will also have group activities that address relevant topics.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Multidisciplinary team based care every 3 months.
Study: NCT06607744

Intervention type: DRUG
Intervention: Pharmacokinetic profiles of Selegiline TDS and EMSAM
Description: Selegiline concentrations will be measured in blood plasma using a validated liquid chromatography tandem mass spectrometry method from Selegiline TDS (test formulation 6mg/24 hours) and EMSAM (6mg/24 hours). The analytical laboratory will be blinded as to samples which are the test and reference products.

Intervention type: DRUG
Intervention: Pharmacokinetic profiles of Selegiline TDS and EMSAM
Description: Selegiline concentrations will be measured in blood plasma using a validated liquid chromatography tandem mass spectrometry method from Selegiline TDS (test formulation 6mg/24 hours) and EMSAM (6mg/24 hours). The analytical laboratory will be blinded as to samples which are the test and reference products.
Study: NCT05151445

Intervention type: BEHAVIORAL
Intervention: mHealth dietary app + health coaching intervention
Description: The Lose-It app will be set up with Gmail accounts with unique unidentifiable codes developed by the research team. Participants be trained to enter their dietary intake and physical activity daily for 12-weeks. Participants will monitor their vegetable intake, fat intake, carbohydrate intake, weight, and blood pressure. Wi-Fi connected weight scales and blood pressure cuff will be supplied for weight and blood pressure monitoring. Participants will be taught how to sync the data from the scales and blood pressure cuff to the app for the research team to access. Participants will perform a return demonstration to confirm that they can record their dietary intake daily, physical activity, weight, and blood pressure using the Lose-It app. We also review with the participant the My Plate method for proper nutrition and the steps to distance conversion chart.
Study: NCT06519279

Intervention type: DEVICE
Intervention: Axivity
Description: At the end of the first session, participants with FOG, will be fitted with an Axivity monitor. This is wearable sensor that will be attached to the participant's lower back (lumbar vertebrae 4-5) with hypoallergic medical tape by the researcher, and will be worn continuously for seven days.~The Axivity monitor is a small (23 x 32.5 x 8.9 mm) and lightweight (11g) device that measures mobility via a tri-axial accelerometer and gyroscope and stores this data onboard, no GPS or other localization options are possible with this monitor. Participants will be given following guidelines concerning the use:~The sensor is to be worn continuously during the seven-day period, i.e. also while sleeping and showering.~The sensor is waterproof and can be worn during showering.

Intervention type: DEVICE
Intervention: Axivity
Description: At the end of the first session, participants with FOG, will be fitted with an Axivity monitor. This is wearable sensor that will be attached to the participant's lower back (lumbar vertebrae 4-5) with hypoallergic medical tape by the researcher, and will be worn continuously for seven days.~The Axivity monitor is a small (23 x 32.5 x 8.9 mm) and lightweight (11g) device that measures mobility via a tri-axial accelerometer and gyroscope and stores this data onboard, no GPS or other localization options are possible with this monitor. Participants will be given following guidelines concerning the use:~The sensor is to be worn continuously during the seven-day period, i.e. also while sleeping and showering.~The sensor is waterproof and can be worn during showering.
Study: NCT05930106

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative fluid ratio
Description: This ratio is calculated by dividing the sum of procedure subcutaneous infiltration and intravenous fluid by the total aspirate volume during surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid Artery Doppler Peak Velocity Variation
Description: Patients will be given a fluid maintenance rate of 1.5 ml/kg/h. To determine fluid responsiveness, the carotid artery peak velocity variation (ΔVPeak-CA) will be measured before, during, and after the procedure. If the ΔVPeak-CA goes above 15%, the patient will receive a fluid bolus of lactated ringer solution at a rate of 4-6 ml/kg over 10-15 minutes, and the team will re-measure fluid responsiveness 10 minutes after each ΔVPeaK-CA.
Study: NCT05737602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3RP-VHL
Description: An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals with VHL.
Study: NCT06121492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acid
Description: In the BCAA group, participants will receive oral BCAA for 24 weeks, with a daily dosage of approximately 13.68 g/day. Each sachet of BCAA will contain 6.84 g of BCAA (valine 1.82 g, leucine 3.29 g, isoleucine 1.72 g), total protein 17.08 g, carbohydrates 25.48 g, fat 5.66 g, providing 221.2 kcal of energy. Each sachet weighs 52 g and should be mixed with 150 ml of water. Participants will consume 2 sachets daily, one after breakfast and one after dinner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo group, BCAA will be replaced with maltodextrin. Each sachet of the placebo will contain a total of 5.93 g of protein, 35.87 g of carbohydrates, 6.00 g of fat, providing 221.2 kcal of energy. Like the BCAA sachets, each placebo sachet will weigh 52 g and should be mixed with 150 ml of water. Participants in the placebo group will consume 2 sachets daily, one after breakfast and one after dinner.
Study: NCT05613985

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care alone
Description: Usual Care is defined as the following procedures to apply to the foot ulcer, carried out in the order in which they are listed:~Sharp debridement (the debridement will be performed only if non-vital tissue is present), Mild washing of the whole ulcer with physiological solution, Treatment with topical antiseptic containing Iodopovidone, Covering with iodopovidone impregnated gauze while the ulcer is clinically infected (PEDIS ≥ 2) \[If, during the study, PEDIS is \< 2, the ulcer will be covered with nonadherent paraffin gauze\].~Treatment 2 times a week (4 treatment weeks, 8 treatments).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care
Description: System VULNOFAST® plus / VULNOLIGHT®: VULNOFAST® plus sterile solution, in combination with a red light source VULNOLIGHT®. VULNOFAST® plus and VULNOLIGHT® will be used in accordance with their Instructions for Use (IFU) and User Manual.~Treatments 2 times a week (4 treatment weeks, 8 treatments of Usual Care and 8 treatments of system VULNOFAST® plus / VULNOLIGHT®).
Study: NCT05774704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low curcumin group
Description: One curcumin capsule (250 mg curcumin) after each meal, 3 times a day for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High curcumin group
Description: One curcumin capsule (500 mg curcumin) after each meal, 3 times a day for 2 weeks.
Study: NCT05869123

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Online adaptive radiotherapy
Description: PTV with 5 margins covers CTV
Study: NCT05812612

Intervention type: DRUG
Intervention: ursodeoxycholic acid
Description: To study the incidence of COVID-19 infection and COVID-19 pneumonia in patients with autoimmune liver disease treated by UDCA, and to explore the impact of UDCA on COVID-19 infection, disease occurrence and clinical outcome.
Study: NCT05376124

Intervention type: OTHER
Intervention: original therapy
Description: * Patients on ETV 0.5mg/ day or TDF 300mg/ day or TAF 25mg/ day continued the original regimen (ETV 1.0mg/ day or TDF 300mg/ day or TAF 25mg/ day), Oral treatment lasted 48 weeks ②Patients who received TDF 300mg/ day plus ETV 0.5mg/ day on initial treatment continued with the original regimen (TDF 300mg/ day plus ETV 0.5mg/ day) and oral therapy for 48 weeks ③Patients who received TAF 25mg/ day plus ETV 0.5mg/ day as initial treatment continued the original regimen (TAF 25mg/ day plus ETV 0.5mg/ day) for 48 weeks of oral therapy

Intervention type: OTHER
Intervention: rescue therapy
Description: TDF 300mg/ day +ETV 1.0mg/ day or TAF 25mg/ day +ETV 1.0mg/ day, oral treatment for 48 weeks.
Study: NCT06636539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEM Exam in Investigational Device
Description: All subjects enrolled in this study will undergo a CEM exam using Investigational Device.
Study: NCT05796557

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Transfusion
Description: Participants will be transfused according to the assigned threshold for each group, with a transfusion dose of 10 mL/kg, up to one adult unit.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Transfusion
Description: Participants will be transfused according to the assigned threshold for each group, with a transfusion dose of 10 mL/kg, up to one adult unit.
Study: NCT06517225

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual-acoustic biofeedback
Description: Behavioral: Visual-acoustic biofeedback In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. The web-based software staRt will be used for intervention delivery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual-acoustic biofeedback
Description: Behavioral: Visual-acoustic biofeedback In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. The web-based software staRt will be used for intervention delivery.
Study: NCT05742516

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bimuno Daily
Description: Galactooligosaccharide supplement within Bimuno Daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin powder
Study: NCT05332743

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrafol Vegan Women's Hair Supplement
Description: Nutrafol's Vegan Women's Hair Supplement with patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. These ingredients include Sensoril Ashwagandha, Curcumin, Saw Palmetto, 20% Tocotrienol/Tocopherol complex, and capsaicin in combination with other vegan nutrients used to support hair health such as Pea Sprout Extract, Bamboo, and a new innovative Maldavian Dragonhead flower extract.
Study: NCT05951075

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Power Prenatal for Sperm
Description: A prenatal vitamin complex that includes numerous ingredients aim at improving sperm quality (ingredients: https://birdandbe.com/the-power-prenatal-for-sperm
Study: NCT06438016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Training
Description: The intervention will comprise of 4 sessions delivered over 4 weeks. The training session will be structured as follows: Session 1 - Psychoeducation relating to stress and its effects. Session 2 - Behavioral techniques to cope with stress 1, Session 3 - Cognitive techniques to cope with stress and Session 4- Behavioral techniques to cope with stress. Both verbal and written means will be used to provide this training.
Study: NCT05818956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-227
Description: TAK-227 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-227
Description: TAK-227 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-227
Description: TAK-227 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-227
Description: TAK-227 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-227
Description: TAK-227 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-227
Description: TAK-227 capsules.
Study: NCT02802423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLEX 404 Oral Liquid
Description: BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.
Study: NCT06359041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CABA-201
Description: Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Study: NCT06270836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarcocimab
Description: Intravitreal injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.
Study: NCT05645406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogel 0.06 % Topical Gel
Description: estradiol topical products

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compounded estradiol product
Description: estradiol topical products
Study: NCT05917496

Intervention type: OTHER
Intervention: LENA tool: Language ENvironment Analysis
Description: Recording of the language environment of the child at home, in daily environment, with the LENA.~The parameters recorded relate to four domains: adult words, conversation turns, child vocalizations and exposure to electronic media.~The LENA box is worn for 10-16 hours, with a minimum of 10 consecutive hours. the families make 2 separate recordings of 6 months at T1 and T2.

Intervention type: BEHAVIORAL
Intervention: Return of the analysis of the data of LENA
Description: The analysis of the LENA data is carried out by the speech therapist using the LENA Pro Version Software v3.4, during the times T1 and T2. The return of the analysis of the data collected via the LENA will be made to the family of the patient after T1 and after T2 and personalized advice will then be given to parents with the aim of improving their child's language skills.
Study: NCT05850663

Intervention type: OTHER
Group type: OTHER
Intervention: Ecologic Momentary Assessment (EMA)
Description: EMA enables measurement of phenomena in real-time, natural settings.~EMA data will be used to identify moments of high distress, assess cancer treatment side effects, and assess barriers to care.~The EMA methodology used in this study will ask about current emotional, physical, behavioral, and social states.~The EMAs will consist of time-based sampling (i.e. a daily dairy), which will be prompted and initiated by the phone.
Study: NCT06167291

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm 1- Ipsilateral
Description: Given by I-RT
Study: NCT05098574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yaz
Description: Continuous treatment with 3mg drospirenone/ 0.02mg ethinyl estradiol for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Appearance, packaging, and labeling of placebo will be matched to their active counterpart.
Study: NCT06220201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-97540
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-97540
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-97540
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days
Study: NCT05455697

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab and Hyaluronidase Human
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given vincristine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET
Study: NCT06220201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days
Study: NCT05455697

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG-CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Given IV
Study: NCT06182475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPPComm Provider Training
Description: A curriculum will be developed to educate patients about LDKT and promote the search of potential living donors while supporting patients' values and cultural preferences. The curriculum will consist of two components: didactic education and skills-based communication. The didactic component provides evidence of the impact of patient-provider communication and LDKT process outcomes for Black and Caucasian patients. The skills-based component will build communication confidence leading discussions about LDKT. It provides instructions for the key communication skills needed to confidently assuage patients' concerns about LDKT/live donation and motivates patients to search for living donor. The following will be covered: providing LDKT information/answering questions, highlighting LDKT benefits, refuting live donation misinformation, and encouraging patients to seek living donors.
Study: NCT06777758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol dose reduction ratio

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol dose reduction ratio
Study: NCT06220201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days
Study: NCT06294613

Intervention type: DEVICE
Group type: OTHER
Intervention: vitreoretinal surgery
Description: Patients undergoing vitreoretinal surgery
Study: NCT05463341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fentanyl Test Strips
Description: A brief fentanyl test strip (FTS) education intervention will be given to participants at Project DAWN sites in the intervention arm after enrollment and collecting baseline data. It will be offered one-on-one with participants and will include the purpose, benefits, and limitations of FTS testing, and information on how to use FTS, interpret the results, what to do if the FTS is positive, and how to use FTS for different drug delivery methods. Participants will practice and demonstrate use of the FTS, and the short video on how to interpret the FTS will include an on-camera statement on the importance of testing for fentanyl. The video will be accessible to participants after study enrollment. Participants will be advised of the possibility of both false positive/negative results, and that the drugs may be mixed with other substances not detectable with FTS. Participants will be encouraged to practice other harm reduction strategies.
Study: NCT04109638

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endonovo SofPulse
Description: The active device emits PEMF signal whereas the placebo device does not emit a PEMF signal. The active device is on for 15 minutes at a time, every two hours, for 10 days.
Study: NCT05716113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD13-02 cell infusion
Description: CAR-T cells
Study: NCT05142215

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention using drug eluting stents and contemporary CTO PCI techniques on background of optimal medical therapy.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo percutaneous coronary intervention
Description: Placebo percutaneous coronary intervention procedure on background of optimal medical therapy.